SA PRO
Free Account
Keros Therapeutics, Inc.KROSNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 56% recommend buying.

Consensus Rating
Buy
16 analysts·Moderate coverage
56%
Rating Distribution
Strong Buy
00%
Buy
956%
Hold
744%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 5, 2024Jefferies
Jefferies Starts Keros Therapeutics (KROS) at Buy
Target:$107.00
+72.5%from $62.02
Nov 5, 2024Truist Financial
Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS)
Target:$100.00
+61.2%from $62.02
Sep 23, 2024Guggenheim
Guggenheim Starts Keros Therapeutics (KROS) at Buy
Target:$96.00
+72.0%from $55.80
Jun 18, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS)
Target:$105.00
+135.2%from $44.65
Dec 13, 2022BTIG
BTIG Maintains Buy on Keros Therapeutics, Raises Price Target to $105
Target:$105.00
+110.1%from $49.98
Jul 27, 2022BTIG
Keros Therapeutics (KROS) Stock: Why It Surged 11.43% Today
Target:$80.00
+151.7%from $31.79
May 18, 2022Piper Sandler
Keros Therapeutics price target raised to $120 from $90 at Piper Sandler
Target:$120.00
+200.6%from $39.92

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance